Characterisation of Levonorgestrel-Resistant Endometrial Cancer Cells

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83(2):388–393. doi:10.1006/gyno.2001.643411606102
   PubMed Web of Science ®Google Scholar
• Gottwald L, Pluta P, Piekarski J, et al. Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2010;6(6):937–944. doi:10.5114/aoms.2010.1930522427770
   PubMed Web of Science ®Google Scholar
• Koh W-J, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(2):170–199. doi:10.6004/jnccn.2018.0006
   PubMed Web of Science ®Google Scholar
• Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol. 2005;193(5):1640–1644. doi:10.1016/j.ajog.2005.05.00316260203
   PubMed Web of Science ®Google Scholar
• McMahon MD, Scott DM, Saks E, Tower A, Raker CA, Matteson KA. Impact of obesity on outcomes of hysterectomy. J Minim Invasive Gynecol. 2014;21(2):259–265. doi:10.1016/j.jmig.2013.08.70724012923
   PubMed Web of Science ®Google Scholar
• Acharya S, Esthappan J, Badiyan S, et al. Medically inoperable endometrial cancer in patients with a high body mass index (BMI): patterns of failure after 3-D image-based high dose rate (HDR) brachytherapy. Radiother Oncol. 2016;118(1):167–172. doi:10.1016/j.radonc.2015.12.01926743834
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–2618. doi:10.1200/JCO.2012.48.259623733771
   PubMed Web of Science ®Google Scholar
• Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196–1208. doi:10.1016/S0140-6736(09)61460-419801098
   PubMed Web of Science ®Google Scholar
• Wilson C, Tobin S, Young R. The exploding worldwide cancer burden. Int J Gynecol Cancer. 2004;14(1):1–11.
   PubMed Web of Science ®Google Scholar
• Mountzios G, Pectasides D, Bournakis E, et al. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol. 2011;79(3):278–292. doi:10.1016/j.critrevonc.2010.07.01320833559
   PubMed Web of Science ®Google Scholar
• Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009;5(3):561–574.19707273
   PubMedGoogle Scholar
• Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–116. doi:10.1097/AOG.000000000000239029215513
   PubMed Web of Science ®Google Scholar
• Behrouzi R, Ryan NAJ, Barr CE, et al. Baseline serum HE4 but not tissue HE4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer. Cancers. 2020;12(2):276. doi:10.3390/cancers12020276
   PubMed Web of Science ®Google Scholar
• Westin SN, Fellman B, Sun CC, et al. Prospective Phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2020;224(2):191–e1.32805208
   PubMed Web of Science ®Google Scholar
• Janda M, Robledo KP, Gebski V, et al. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: results of a randomized clinical trial. Gynecol Oncol. 2021;161(1):143–151. doi:10.1016/j.ygyno.2021.01.02933762086
   PubMed Web of Science ®Google Scholar
• Gallos I, Alazzam M, Clark T, et al. Management of endometrial hyperplasia. Green-top guideline no. 67. In: RCOG/BSGE Joint Guideline. 2016. London: Royal College of Obstetricians and Gynaecologists;2016.
   Google Scholar
• Barr CE, Crosbie EJ. Mirena coil is a suitable treatment of early-stage endometrial cancer in obese women. BJOG. 2020;127(8):1001.32350976
   PubMed Web of Science ®Google Scholar
• Dore M, Filoche S, Danielson K, Henry C. Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: can biomarkers predict response? Gynecol Oncol Rep. 2021;36:100732. doi:10.1016/j.gore.2021.10073233718563
   PubMed Web of Science ®Google Scholar
• Janzen DM, Rosales MA, Paik DY, et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res. 2013;73(15):4697–4710. doi:10.1158/0008-5472.CAN-13-093023744837
   PubMed Web of Science ®Google Scholar
• Reyes HD, Carlson MJ, Devor EJ, et al. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Gynecol Oncol. 2016;140(1):152–160. doi:10.1016/j.ygyno.2015.10.02326524723
   PubMed Web of Science ®Google Scholar
• Li W, Wang S, Qiu C, et al. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line. J Transl Med. 2019;17(1):58. doi:10.1186/s12967-019-1814-630813939
   PubMed Web of Science ®Google Scholar
• Barros FSV, Brosens JJ, Brighton PJ. Isolation and primary culture of various cell types from whole human endometrial biopsies. Bio-Protocol. 2016;6(22):e2028. doi:10.21769/BioProtoc.2028
   Google Scholar
• Skok K, Maver U, Gradišnik L, Kozar N, Takač I, Arko D. Endometrial cancer and its cell lines. Mol Biol Rep. 2020;47(2):1399–1411. doi:10.1007/s11033-019-05226-331848918
   PubMed Web of Science ®Google Scholar
• Qu W, Zhao Y, Wang X, et al. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines. Clinica Chimica Acta. 2019;489:225–232. doi:10.1016/j.cca.2018.08.013
   PubMed Web of Science ®Google Scholar
• McDermott M, Eustace AJ, Busschots S, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol. 2014;4:40. doi:10.3389/fonc.2014.0004024639951
   PubMedGoogle Scholar
• Henry C, Llamosas E, Knipprath-Meszaros A, et al. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget. 2015;6(37):40310–40326. doi:10.18632/oncotarget.564326515598
   PubMedGoogle Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675. doi:10.1038/nmeth.208922930834
   PubMed Web of Science ®Google Scholar
• Gebäck T, Schulz MMP, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. BioTechniques. 2009;46(4):265–274. doi:10.2144/00011308319450233
   PubMed Web of Science ®Google Scholar
• Vinci M, Box C, Eccles SA. Three-dimensional (3D) tumor spheroid invasion assay. J Vis Exp. 2015;99:e52686.
   Google Scholar
• Henry C, Quadir A, Hawkins NJ, et al. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol. 2015;141(2):243–254. doi:10.1007/s00432-014-1824-y25209439
   PubMed Web of Science ®Google Scholar
• Henry C, Hacker N, Ford C. Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget. 2017;8(68):112727–112738. doi:10.18632/oncotarget.2255929348860
   PubMedGoogle Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumour subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):659. doi:10.1016/j.neo.2017.05.00228739011
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.24556840
   PubMed Web of Science ®Google Scholar
• Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015;35:S25–S54.25892662
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–4751. doi:10.1038/onc.2010.21520531305
   PubMed Web of Science ®Google Scholar
• Ørbo A, Arnes M, Lyså LM, Borgfelt C, Straume B. HE4 is a novel tissue marker for therapy response and progestin resistance in medium-and low-risk endometrial hyperplasia. Br J Cancer. 2016;115(6):725–730. doi:10.1038/bjc.2016.24727537387
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–364. doi:10.1038/nature1262724048068
   PubMed Web of Science ®Google Scholar
• Stanta G, Bonin S. Overview on clinical relevance of intra-tumor heterogeneity. Front Med. 2018;5(85). doi:10.3389/fmed.2018.00085
   Web of Science ®Google Scholar
• Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–345. doi:10.1038/nature1262524048066
   PubMed Web of Science ®Google Scholar
• Ghaleb AM, Yang VW. Krüppel-like factor 4 (KLF4): what we currently know. Gene. 2017;611:27–37. doi:10.1016/j.gene.2017.02.02528237823
   PubMed Web of Science ®Google Scholar
• Lung HL, Kan R, Chau WY, et al. The anti-tumor function of the IKK inhibitor PS1145 and high levels of p65 and KLF4 are associated with the drug resistance in nasopharyngeal carcinoma cells. Sci Rep. 2019;12064(9):1.
   Google Scholar
• Jiang Z, Zhang Y, Chen X, Wu P, Chen D. Long non-coding RNA LINC00673 silencing inhibits proliferation and drug resistance of prostate cancer cells via decreasing KLF4 promoter methylation. J Cell Mol Med. 2020;24(2):1878–1892. doi:10.1111/jcmm.1488331881124
   PubMed Web of Science ®Google Scholar
• Deng X, Kong F, Li S, et al. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer. Cell Death Dis. 2021;485(12):1–3.
   Google Scholar
• Jia Y, Zhou J, Luo X, et al. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Cell Signal. 2018;42:165–175. doi:10.1016/j.cellsig.2017.09.02528988130
   PubMed Web of Science ®Google Scholar
• Lee SI, Kim DK, Seo EJ, et al. Role of Krüppel-like factor 4 in the maintenance of chemoresistance of anaplastic thyroid Cancer. Thyroid. 2017;27(11):1424–1432. doi:10.1089/thy.2016.041428920531
   PubMed Web of Science ®Google Scholar
• Schoenhals M, Kassambara A, Veyrune JL, et al. Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma. Haematologica. 2013;98(9):1442. doi:10.3324/haematol.2012.06694423585530
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Takeuchi T, Mita S, et al. Krüppel-like factor 4 mediates anti-proliferative effects of progesterone with G0/G1 arrest in human endometrial epithelial cells. J Endocrinol Invest. 2010;33(10):745–750. doi:10.1007/BF0334668120479568
   PubMed Web of Science ®Google Scholar
• Ghaleb AM, Katz JP, Kaestner KH, et al. Krüppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene. 2007;26(16):2365–2373. doi:10.1038/sj.onc.121002217016435
   PubMed Web of Science ®Google Scholar
• Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptio na l repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol. 2005;7(11):1074–1082. doi:10.1038/ncb131416244670
   PubMed Web of Science ®Google Scholar
• Eaton JL, Unno K, Caraveo M, et al. Increased AKT or MEK1/2 activity influences progesterone receptor levels and localization in endometriosis. J Clin Endocrinol Metab. 2013;98(12):E1871–E18. doi:10.1210/jc.2013-166124064688
   PubMed Web of Science ®Google Scholar
• Akesson E, Gallos ID, Ganesan R, et al. Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena®) treatment of endometrial hyperplasia: an immunohistochemical study. Acta Obstet Gynecol Scand. 2010;89(3):393–398. doi:10.3109/0001634090355600620199355
   PubMed Web of Science ®Google Scholar
• Fawzy M, Mosbah A, Zalata K, et al. Predictors of progestin therapy response in endometrial hyperplasia: an Immunohistochemical Study. Egypt J Fertil Steril. 2016;20(2):6–11. doi:10.21608/egyfs.2016.19528
   Google Scholar
• Tang G, Liu D, Xiao G, et al. Transcriptional repression of FOXO1 by KLF4 contribute s to glioma progression. Oncotarget. 2016;7(49):81757–81767. doi:10.18632/oncotarget.1318427835585
   PubMedGoogle Scholar
• Uhlén M, Fagerberg L, Hallstrom BM. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. PubMed: 25613900. doi:10.1126/science.126041925613900
   PubMed Web of Science ®Google Scholar
• Sato S, Maekawa R, Tamura I, et al. SATB2 and NGR1: potential upstream regulatory factors in uterine leiomyo mas. J Assist Reprod Genet. 2019;36(11):2385–2397. doi:10.1007/s10815-019-01582-y31728810
   PubMed Web of Science ®Google Scholar
• Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016;40(3):419–432. doi:10.1097/PAS.000000000000055326551622
   PubMed Web of Science ®Google Scholar
• Sletten ET, Smaglyukova N, Ørbo A, Sager G. Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy. J Steroid Biochem Mol Biol. 2020;202:105701. doi:10.1016/j.jsbmb.2020.10570132479983
   PubMed Web of Science ®Google Scholar
• Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015;21(2):155–173. doi:10.1093/humupd/dmu05625406186
   PubMed Web of Science ®Google Scholar
• Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol. 2001;54(8):624–630. doi:10.1136/jcp.54.8.62411477119
   PubMed Web of Science ®Google Scholar
• Yang X, Kui L, Tang M, et al. High-throughput transcriptome profiling in drug and biomarker discovery. Front Genet. 2020;11:19. doi:10.3389/fgene.2020.0001932117438
   PubMed Web of Science ®Google Scholar
• Kapałczyńska M, Kolenda T, Przybyła W, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14(4):910–919.30002710
   PubMed Web of Science ®Google Scholar